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Abstract 
Untreated chronic myeloid leukemia (CML) progresses from chronic phase to blastic 
crisis. Increased genomic instability, deregulated proliferation and loss of differentiation 
appear associated to blastic crisis, but the molecular alterations underlying the 
progression of CML are poorly characterized. MYC oncogene is frequently deregulated in 
human cancer, often associated with tumor progression. Genomic instability and induction 
of aberrant DNA replication are described effects of MYC. In this report we studied MYC 
activities in CML cell lines with conditional MYC expression with and without exposure to 
imatinib, the front-line drug in CML therapy. In cells with conditional MYC expression MYC 
did not rescue the proliferation arrest mediated by imatinib but provoked aberrant DNA 
synthesis and accumulation of cells with 4C content. We studied MYC mRNA expression 
in 66 CML patients at different phases of the disease, and we found that MYC expression 
was higher in CML patients at diagnosis than control bone marrows or in patients 
responding to imatinib. Further, high MYC levels at diagnosis correlated with a poor 
response to imatinib. MYC expression did not directly correlate with BCR-ABL levels in 
patients treated with imatinib. Overall our study suggests that, as in other tumor models, 
MYC-induced aberrant DNA synthesis in CML cells is consistent with MYC 
overexpression in untreated CML patients and non-responding patients and supports a 
role for MYC in CML progression, possibly through promotion of genomic instability.  
 
 
Introduction 
c-Myc (MYC herein after) is an oncogenic transcription factor of the helix-loop-
helix/leucine zipper protein family. MYC is a widespread regulator of transcription that 
directly or indirectly regulates about one thousand genes, and binds to 15% of genomic 
loci [reviewed in (1, 2)]. MYC is found deregulated in nearly half of human tumors and 
appears frequently associated with tumor progression (3, 4). However, as most human 
tumors are relatively advanced at the time of discovery it is difficult to ascertain whether 
MYC became deregulated at an early or late stage of disease progression. A number of 
tumor-related activities have been described for MYC such as the increased proliferative 
potential, enhanced protein synthesis and energetic metabolism, differentiation arrest and 
genomic instability (2, 5). Genomic instability is thought to be essential for MYC-induced 
carcinogenesis, as demonstrated in cell culture and mouse models [reviewed in (6, 7)]. 
Mechanisms for MYC-mediated genomic instability include the disruption of cell cycle 
checkpoints (2, 8), disruption of DNA repair (9) and unscheduled DNA replication (10-14). 
An increasing role of MYC in inducing DNA synthesis in conditions of cell stress has been 
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gathering over the last years [reviewed in (15)]. In cell culture models this abnormal 
induction of DNA synthesis often results in aberrant or “illegitimate” DNA synthesis 
uncoupled from cell division, leading to G2 arrest and/or polyploidy (16-18). 
Chronic myeloid leukemia (CML) is a myeloproliferative disorder that represents 15-
20% of newly diagnosed leukemias. CML progresses in three phases: most of the patients 
are diagnosed in a relatively benign chronic phase (CP) followed by an accelerated phase 
and finally a blastic crisis (BC) phase (19). The molecular hallmark of all CML phases is 
the expression of the Bcr-Abl kinase and the BCR-ABL inhibitor Imatinib (“Gleevec”) is 
today the frontline drug in CML therapy (20-22). However, despite the efficacy of imatinib 
in prolonging the CP, there is a significant fraction of patients that fail to respond and thus 
frequent monitoring is needed (23, 24). It is believed that CML is a stem cell malignancy in 
which BCR-ABL would lead to a progressive block of differentiation and increased genetic 
instability (22, 25-27). However, the mechanisms underlying CML progression are still 
uncertain. As BCR-ABL is already present in CP, it is assumed that progression is a 
multistep, time-dependent process that requires the mutation or deregulation of additional 
genes. Actually, BCR-ABL expression levels or phosphorylation of BCR-ABL substrates do 
not fully determine the prognosis for individual patients (25, 28). This has driven the search 
for other genes that could serve as molecular markers for CML progression. Different 
large-scale genomic profiling studies have identified a series of candidate genes, but these 
vary significantly across different studies [reviewed in (22, 25)]. The involvement of MYC in 
CML has not been fully addressed. However, CML constitutes an interesting tumor to 
study MYC involvement because (i) CML begins in the more benign chronic phase which 
can be significantly extended by imatinib treatment; (ii) samples from the same patient can 
be analyzed for MYC expression at different stages along the evolution of the leukemia; 
(iii) BCR-ABL up-regulates MYC expression (29-31) and MYC cooperates with BCR-ABL 
in transformation (32-34)  and (iv) MYC activities in genomic instability and differentiation 
arrest have been associated to CML progression (22, 25). However, MYC expression in 
the different CML phases and in relation to treatment response is so far unreported. 
Studies performed with a small number of cases reported that MYC mRNA levels are 
either elevated or unchanged in CML-BC (35-39). It is also of note that trisomy 8 and gain 
at 8q24 (where MYC maps) are among the most frequent cytogenetic alterations in CML 
(40, 41). 
Here we first demonstrate that, in the presence of imatinib, MYC promotes 
aberrant DNA replication (uncoupled from mitosis), a MYC activity related to genomic 
instability. Consistently, we also found increased MYC expression in untreated CML 
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cases. Moreover, we found a positive correlation between MYC expression at diagnosis 
and poor response to imatinib, which is not directly dependent on BCR-ABL expression.  
 
 
Results  
Ectopic MYC increased DNA synthesis in K562 cells treated with imatinib.  
We previously reported that imatinib provoked a dramatic down-regulation of MYC 
in K562 and other CML-derived cell lines (30) and it is reported that  MYC can induce 
unscheduled DNA synthesis in conditions of cell stress (15). Therefore, we asked whether 
MYC could reverse the arrest in DNA synthesis and cell growth provoked by imatinib. We 
used the KmycB cell line, a derivative of the CML cell line K562 carrying a Zn2+-inducible 
MYC allele (42). As reported for parental cells, imatinib repressed MYC (30), but the 
addition of the inducer (ZnSO4) increased exogenous MYC mRNA levels even in the 
presence of imatinib in KmycB cells (Fig. 1A). The decrease in MYC 24-48 h after ZnSO4 
addition is already reported (42). It is due to the inducible system used, based on the 
metallothionein promoter, and occurs with other genes driven by this promoter in K562 
cells (43, 44). MYC protein was also detected at significant levels in KmycB cells treated 
with ZnSO4 and imatinib, assessed by immunoblot (Fig. 1B). It is important to note that in 
this model system, the levels of MYC mRNA and protein achieved upon induction in the 
presence of imatinib are not supra-physiological but similar or lower to those of control 
untreated cells. However, MYC did not modify the proliferation arrest mediated by imatinib 
(Fig. 1C). We next asked whether MYC could induce DNA synthesis uncoupled from 
mitosis, a marker of MYC activity in genomic instability (see Introduction). DNA synthesis, 
determined by 3H-thymidine incorporation, was halted in parental cells after imatinib 
treatment but significantly increased upon induction of MYC in KmycB cells in the 
presence of imatinib (Fig. 1D). The increased DNA synthesis in imatinib-treated cells 
upon MYC induction was also observed by measuring DNA synthesis through the 
incorporation of BrdU in KmycB cells (Fig. 1E). Similar results were obtained with KmycJ 
cells, another MYC-inducible K562 line (42) (data not shown). As mRNA synthesis of the 
nucleosomic histones genes is concomitant with DNA replication, we determined mRNA 
levels of histone H4. We found that the stimulation of DNA synthesis mediated by MYC 
was accompanied by the up-regulation of histone H4 mRNA as shown by northern 
analysis (Fig. 1A).  
As MYC induced DNA synthesis but not mitosis in the presence of imatinib in 
KmycB cells, we expected that MYC induced accumulation of cells with >2C DNA 
content, as reported in other models (16-18). This was indeed observed by cell cycle 
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analysis in KmycB, which showed a higher fraction of cells with 4C DNA content in the 
cells treated with imatinib and ZnSO4 with respect to cells treated only with imatinib (Fig. 
1F and Supplementary Fig.S1). This effect is clearly detected after 48 h of imatinib 
treatment. However, at longer treatment intervals with 0.5 μM imatinib a significant 
fraction of cells undergo apoptosis (data not shown).  
 The previous results showed that MYC induced DNA synthesis in the presence of 
imatinib in cell lines with Zn-inducible MYC. To more rigorously assess the role of MYC in 
this process we wanted to test a different system of conditional MYC expression. For this 
purpose, we generated a K562 derivative, termed KMER4, expressing a chimerical 
protein with MYC fused with the hormone binding region of the estrogen receptor 
(MycER) (45). Immunoblot analysis demonstrated the expression of MycER at high levels 
(Fig. 2A). The activation of MycER by 4HT in KMER4 cells was assessed, first, by the 
MYC down-regulation of endogenous MYC (Fig. 2A), an effect observed in many cell 
lines, including K562 (42, 46). We further confirmed the activation of MycER by 4HT 
through transactivation assays of a luciferase reporter carrying four MYC-responsive E-
boxes (Fig. 2B). Similarly to the previous observation on KmycB cells, the activation of 
MYC by 4HT did not rescue the proliferation arrest elicited by imatinib in KMER4 cells 
(Fig. 2C). However, MYC activation augmented the DNA synthesis as measured by 3H-
thymidine incorporation (Fig. 2D) as well as by BrdU incorporation (Fig. 2E). The analysis 
of DNA content by PI staining and flow cytometry demonstrated an accumulation of cells 
with 4C DNA content (Fig. 2F and Supplementary Fig.S1). We carried out a double 
staining of PI and BrdU in KMER cells treated with imatinib and 4HT. The results 
confirmed that the cells with 4C content also incorporated BrdU (Fig. 2G). Thus, the 
results in KMER4 cells are similar to those observed in KmycB, i.e., that conditional 
activation of MYC provoked aberrant DNA synthesis in cells exposed to imatinib. Like 
many CML-derived cell lines, K562 carries mutated TP53 alleles. Nonetheless, an 
important fraction of CML in blast crisis carry wild-type TP53 (25) and a dependence on 
p53 for MYC-driven genomic instability has been reported in some models (47-49). 
However, using a K562 derivative with conditional p53 expression (50), we found that 
MYC can also induce G2 accumulation in the presence of imatinib in cells with active p53 
(Supplementary Fig. S2). BCR-ABL induces MCY levels through JAK2 and that JAK2 
regulates BCR-ABL signalling (29, 31). However, MYC activation in our K562 models did 
not reverse the JAK2 inactivation induced by imatinib (not shown). 
The former results show a MYC-mediated accumulation of cells with 4C DNA 
content when cells are exposed to imatinib and MYC is activated, but, noticeably, MYC 
did not induce cell proliferation. A possible explanation of this result is that MYC is 
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stimulating proliferation which is balanced by MYC-mediated apoptosis. We analysed the 
effect of MYC on imatinib-mediated apoptosis by determining the fraction of cells with a 
sub-diploid DNA content by flow cytometry of PI-stained cells. The results showed that 
imatinib induced apoptosis (25-30% of apoptotic cells after 48 h) but MYC did not modify 
this result in KmycB cells (Fig. 3A). We sought to confirm this result assessing apoptosis 
by a different method, i.e., the binding to annexin V. The results again showed that MYC 
did not significantly increase apoptosis induced by imatinib (Fig. 3B). DNA laddering 
assays further confirmed this result (Fig. 3C). The lack of increased apoptosis in cells 
treated with imatinib and with activated MYC was not surprising as the MYC levels 
achieved in ZnSO4-treated cells were not supraphysiological, due to the autoregulatory 
effects of MYC described above (42, 46).   
The results suggest that MYC induces aberrant DNA synthesis in the presence of 
imatinib. Next, we wanted to determine whether the MYC effect depends on imatinib-
mediated inhibition of BCR-ABL kinase activity per se or whether it required the 
proliferation arrest. To address this question we followed two approaches. First, we 
generated a KmycB derivative with constitutive expression of the BCR-ABL-T315I mutant, 
which is resistant to imatinib  (51). These cells were highly resistant to the antiproliferative 
effects of imatinib (IC50 ~ 7 μM). However, endogenous MYC was not downregulated by 
imatinib and the induction of MYC did not modify the cell cycle profile of these cells treated 
with imatinib, despite that endogenous wild-type BCR-ABL was inhibited (Supplementary 
Fig. S3). Similarly, in K562R cells, which are resistant to imatinib due to LYN kinase 
overexpression (52), MYC was not downregulated by imatinib despite BCR-ABL inhibition 
by imatinib (not shown). In the second approach we generated a KmycB derived cell line 
overexpressing Bcl2, termed KmycBcl2. In contrast to K562, which does not express Bcl2 
(53), KmycBcl2 expressed high levels of Bcl2 as shown by immunoblot (Fig. 3D). We also 
showed that, in KmycBcl2 cells, MYC was efficiently induced by ZnSO4 in the presence of 
imatinib (Fig. 3E). Neither imatinib treatment nor MYC induction by ZnSO4 affected the 
expression the Bcl2 transgene (Fig. 3D). KmycBcl2 cells were resistant to imatinib-
mediated apoptosis (not shown), as previously reported for KLBcl2v cells (30). In 
concordance, KmycBcl2 cells were partly resistant to the antiproliferative effects of 
imatinib, as shown by cell counting (Fig. 3F) and by 3H-thymidine incorporation (Fig. 3G). 
Nonetheless, MYC induction did not modify the effect of imatinib on proliferation (Fig. 3F). 
The induction of MYC in KmycBcl2cells again resulted in augmented DNA synthesis as 
assessed by 3H-Thy incorporation (Fig. 3G). We also determined the DNA content in 
KmycBcl2 cells by PI staining and we found that the fraction of cells with 4C DNA content 
was increased upon MYC induction (Fig. 3H). Noticeably, the cell fraction with 4C content 
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was lower in KmycBcl2 than in KmycB cells, consistent with the partial resistance of 
KmycBcl2 cells to the anti-proliferative effect of imatinib, as compared to cells without Bcl2 
overexpression.  
Taken together, our results indicate that MYC induces unscheduled DNA synthesis 
in the presence of cell proliferation arrest induced by imatinib.  
 
 
MYC expression in CML patients 
The above results suggest the possibility that MYC could promote genomic instability 
in CML cells in vivo and therefore be up-regulated during CML progression. To explore this 
hypothesis we first compared MYC expression levels in bone marrow mononuclear cells 
from patients at diagnosis, CP patients that responded to imatinib, CP patients that did not 
respond (i.e., not achieving CCR) and BC patients (66 patients in total). The samples were 
provided by two different hospitals and their relevant clinicopathological features are 
shown in Table 1. MYC mRNA levels were determined by qRT-PCR and the results 
showed that MYC expression was 2-5-fold higher in patients at diagnosis and non-
responders than in patients responding to imatinib treatment or healthy individuals (Fig. 4A).  
These results suggest that MYC could serve as a predictive marker for the clinical 
response to imatinib. CML natural history allows the determination of the expression of 
MYC in the same patient throughout the leukemia progression. To test the former 
hypothesis, we carried out serial determinations of MYC expression during disease evolution 
in 60 patients. We found that in most of the patients (40 out of 45) that responded to imatinib 
(using CCR as response criteria), MYC expression decreased with treatment or was kept at 
low levels. In contrast, MYC levels did not decrease in non responders. Furthermore, MYC 
expression increased in most of the non responders (11 out of 15) during CML progression. 
Some representative cases are shown in Fig. 4B. The bimodal profile of MYC expression is 
noteworthy in patient 57P, who initially responded to imatinib but after 12 months became 
resistant to treatment as the cells expressed a BCR-ABL G250E mutation. To our knowledge 
this is the first report showing MYC overexpression during the clinical course of CML in 
single patients. In some settings a posttranscriptional regulation of MYC has been 
described (2, 54). Thus we analyzed the expression of MYC at the protein level in bone 
marrow samples from 32 CML patients, 24 at diagnosis and 8 at CMR. Although the number 
of samples analyzed was small, the results demonstrate that the levels of MYC protein in the 
group of samples at diagnosis is clearly higher than in the patients at CMR (Fig. 4C). There 
was concordance between protein and mRNA levels in 9 out of 12 samples where mRNA 
could be analysed (not shown). Thus, the results indicate the increased MYC expression in 
CML occurs also at the protein level 
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MYC mRNA levels are higher in non-responders. 
Low MYC levels in CML could reflect the disappearance of leukemic cells in the 
bone marrow sample. Thus we analyzed the probability of response to imatinib as a 
function of MYC levels in CML patients. We analyzed the relationship between MYC levels 
and CCR as estimated via a random-effects logistic regression model. The results (Fig. 
5A) show that relationship between MYC levels and CCR was Odds Ratio (OR) = 0.92 by 
each 0.01 units of MYC, with a 95% Confidence Interval (CI) = 0.87 - 0.97. The 
relationship between MYC levels and MMR was OR = 0.82 (95% CI: 0.73 - 0.94). The 
estimated probabilities of response to treatment as a function of MYC levels were p = 
0.002 and 0.003 for patients achieving CCR and MMR, respectively (Fig. 5A). Thus, we 
found a relationship between high MYC expression and lack of response (CCR and MMR) 
(Fig. 5A), which was more robust when MMR was used as the response criterion.  
Next we asked whether MYC levels at diagnosis could differentiate between 
responders and non-responders in a prediction model. The results showed that response 
(MMR) was achieved faster in patients with low MYC expression than in those with high 
MYC expression (Fig. 5B), although the difference did not reach significance (p = 0.142). 
The former results strongly suggested an association of high MYC levels with poor or late 
response to treatment. To determine whether MYC expression could classify responder 
and non-responder patients we compared ROC curves with the data of MYC at diagnosis 
and MYC after treatment in responders and non-responders. The results showed that 
MYC expression classified the patients as responders to treatment with remarkable 
specificity and sensitivity (area under the curve = 0.85) (Fig. 5C right panel), whereas it 
did not mark any difference between patients at diagnosis and non-responders (Fig. 5C 
left panel). As a control, expression of BCR-ABL was also plotted. The analysis of the 
ROC curves allows the selection of a MYC cut-off value of 0.058 with a sensitivity of 0.89 
and specificity of 0.65. Remarkably, this cut-off is consistent with the mean MYC value of 
healthy controls and responders (Fig. 4A). 
 
MYC expression does not depend on BCR-ABL mRNA levels. 
Cell culture data indicated that BCR-ABL kinase activity induces MYC and imatinib 
down-regulates MYC in CML-BC-derived cell lines. In clinical samples it is expected that 
high BCR-ABL mRNA expression correlates with high kinase activity. So it was conceivable 
that MYC levels in CML patient cells correlate to those of BCR-ABL, which decrease 
dramatically upon imatinib treatment. However, this correlation has not yet been explored in 
clinical samples. We compared the expression of both genes in our patients and found a 
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positive correlation in samples at diagnosis (Fig. 6). In contrast we did not find such 
correlation in patients undergoing a hematological response where a significant number of 
samples with high BCR-ABL showed relatively low MYC expression (Fig. 6). The lack of 
correlation was also observed in non-responders and blastic crisis samples, although in 
these cases only 9 samples were analyzed (Fig. 6). Therefore, MYC and BCR-ABL levels 
did not correlate in CML patients receiving imatinib treatment. Our results rather suggest 
that MYC levels in CML patients inversely correlate with the normalization of hematopoiesis 
and disappearance of leukemic cells, as already marked by the hematological response. 
 
Discussion  
In this work we describe four novel findings: (i) MYC induces unscheduled or 
aberrant DNA synthesis in CML cells under imatinib stress; (ii) MYC expression is higher in 
untreated CML patients and in those not responding to imatinib treatment; (iii) MYC levels 
at diagnosis could predict the response of the disease to treatment; (iv) the lack of a 
universal correlation between MYC and BCR-ABL expression in CML patients. In two 
CML-derived K562 cell lines with conditional MYC expression (induced by Zn2+ or 
activated by 4HT) we found that ectopic MYC expression did not antagonize imatinib-
mediated growth arrest. However, in cells treated with imatinib, MYC induced both 
aberrant DNA synthesis uncoupled from mitosis, and a moderate accumulation of cells 
with 4C DNA content. Both activities have been associated to MYC-mediated genomic 
instability (10-13, 16-18). Taken together, the results argue for a role of MYC inducing 
illegitimate DNA synthesis in K562 cells under imatinib-mediated stress. The promotion of 
DNA replication in cells subjected to stress has been identified as a major MYC 
oncogenic activity [reviewed in (15)].  
We detected a 2 to 5-fold increase in MYC expression in patients at diagnosis as 
compared to healthy controls and MYC was also increased in patients that failed to respond 
to imatinib treatment. A number of previous reports indicate that this expression difference 
can be relevant for MYC-dependent carcinogenesis. For instance, just a two-fold change 
means a major difference for MYC ability to transform cells in different cell culture models 
(55-57) as well as in transgenic animals where MYC dosage can be modulated (58). It is 
also noteworthy that in Burkitt lymphoma, the paradigm of MYC activation in human cancer, 
MYC increase in expression can be only two-fold with respect to normal lymphocytes (59). 
It is surprising that MYC involvement in CML has gone unnoticed up to now, although the 
microarray expression data of a previous study shows increased MYC expression in 
CD34+ cells from 9 CML patients, as compared to healthy controls (39). Other microarray 
studies have detected upregulation of MYC downstream genes (60-62). A report 
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described similar expression changes in CML progression for BMI1 (63), a polycomb 
group gene that cooperates with MYC in carcinogenesis (64), which was also undetected in 
microarray-based studies. 
The involvement of MYC in CML progression suggested by our data is consistent 
with published data showing the relevance of MYC in experimental myeloid leukemia. For 
instance, in mice where MYC expression is directed to the hematopoietic precursors these 
animals develop acute myeloid leukemia (65). Also, infection of murine bone marrow with 
MYC retroviruses results in myeloid but not lymphoid leukemia (66, 67). Moreover, analysis 
in transgenic models shows that MYC is essential for normal differentiation of myeloid 
stem cells [reviewed in (68)]. 
 How could MYC contribute to CML progression? Our data showing MYC 
overexpression during CML progression is consistent with our studies in CML blast crisis 
cells, where MYC promotes aberrant DNA synthesis under imatinib stress. CML 
progression is associated to increased genomic instability and differentiation arrest, two 
major and well-known MYC activities [reviewed in (6, 7, 69)]. Thus, our data are 
consistent with the finding that higher MYC levels at diagnosis correlate with worse 
response to imatinib. Collectively, our results suggest a role for MYC in CML progression. It 
is conceivable that clones with higher MYC expression are selected during CML 
progression and that high-MYC cells are more prone to progress to BC. Further 
investigation is required to evaluate the usefulness of MYC in the assessment of CML 
prognosis. 
 
 
 
Materials and Methods 
Cell lines, cell proliferation and DNA synthesis assays 
The K562 cell line, derived from CML-BC, was obtained from the American Type Culture 
Collection. KmycB are K562 cells stably transfected with inducible MYC gene (42). To 
generate the KMER4 cell line, K562 cells were electroporated (BioRad Gene Pulser 
apparatus) with pBABEPuro-mycERTM plasmid. This vector expresses the Myc-ER 
chimera, which is activated by 4-hydroxytamoxifen (4HT) (45).  Transfected clones were 
selected with 1 μg/ml of puromycin. KLBcl2v cells are K562 cells expressing Bcl2 (53). To 
generate the KmycBcl2 cell line, KmycB cells were retrovirally transduced with a Bcl2 
expression vector as described (53). To generate the KmycBT315I cell line, KmycB cells 
were electroporated with an expression vector for BCR-ABL-T315I mutant  
(pSRαp210T315I) (70), All cell lines were grown in RPMI 1640 medium (Gibco-Life 
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Sciences) containing 10% fetal calf serum, gentamycin (80 µg/ml) and ciprofloxacin (2.5 
µg/ml). For proliferation assays, exponentially growing cells were plated at a concentration 
of 250,000 cells per ml on day 0. For thymidine incorporation assays, cells were incubated 
with 1 µCi/ml of 3H-thymidine for 2 h, harvested onto glass wool filters and the radioactivity 
was counted by liquid scintillation. To analyze the fraction of cells undergoing DNA 
synthesis, cells were cultured in the presence of 30 µM bromodeoxyuridine (BrdU) for 90 
min and processed as described (71).  
 
Cell cycle and apoptosis analysis 
Cells were resuspended in PBS-sodium citrate buffer containing 10 μg of bovine serum 
albumin/ml, 200 μg of RNAse/ml, and 50 μg/ml of propidium iodide (PI). The cells were 
incubated at 37°C in the dark for 30 min and then analyzed by flow cytometry using 
CellQuest software. For double labeling with BrdU and PI, the cells were pulsed with 10 
µM BrdU for 45 min, harvested, fixed in 75% ethanol at 4ºC, washed with PBS and 
incubated for 20 min with 2 N HCl, neutralized with 0.1 M borate buffer, pH 8.3, washed 
and resuspended in PBS, 5% FCS, 0.5% Tween-20 (PFST). Cells were incubated with an 
anti-BrdU monoclonal antibody (BD Biosciences, diluted 1:100) for 60 min at RT washed, 
and incubated for 60 min with a FITC-conjugated secondary antibody (1:100, Jackson 
Immuno). Cells were washed, and incubated for 2 h with 5 µg/ml PI and 50 µg/ml RNAse 
and the cells were analyzed by flow cytometry. Apoptosis was assessed by annexin V 
binding and internucleosomal DNA fragmentation assays. Annexin V binding was 
detected by flow cytometry using the BD-Pharmingen kit. The presence of 
internucleosomal DNA fragmentation (DNA laddering) after cell exposure to imatinib, was 
analyzed by electrophoresis on a 1.5% agarose gel as previously described (43). 
 
Immunoblots 
K562 cells and bone marrow cells were lysed with 1% NP40 and 0.2% SDS and sonicated. 
The protein levels were determined by immunoblot as described (71). Anti-MYC antibody 
(N-262, rabbit polyclonal), anti-actin (I-19, goat polyclonal) and anti-Bcl2 (C-21, rabbit 
polyclonal), anti ERK2 (C-14, rabbit polyclonal) and anti-α-tubulin (H-300, rabbit polyclonal) 
were from Santa Cruz Biotechnology.  
 
RNA analysis 
Total RNA was prepared with TriReagent (Invitrogen). For Northern analysis, RNAs (15 
μg of total RNA per lane) were separated by electrophoresis through agarose-
formaldehyde gel and transferred to nitrocellulose. Probe labeling with [α-32P]dCTP and 
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filter hybridization were carried out according to standard procedures. Probes for human 
MYC and histone H4 were as described (42). RNA levels in clinical samples were 
determined by quantitative RT-PCR. Reverse transcription and quantitative PCR were 
performed as described (72). MYC expression was normalized against the mRNA levels 
of ribosomal protein S14 (RPS14). The primers for MYC were 5’-
AAGACTCCAGCGCCTTCTCTC-3’ and 5’-GTTTTCCAACTCCGGGATCTG-3’. The 
primers for RPS14 were 5’-TCACCGCCCTACACATCAAACT-3’ and 5’-
CTGCGAGTGCTGTCAGAGG-3’. RPS14 has not been described as a MYC target gene 
(www.myccancergene.org). Primers for BCR-ABL were as described (73). The 
experimental variability was controlled using a control cDNA pool synthesized with RNAs 
from K562 and HeLa cells (50% each). 
 
Luciferase reporter assays 
3 million KMER4 cells were electroporated at 260 V and 1 mFa in a Bio-Rad 
electroporator with 3 µg of pGL2-M4-Luc reporter, which carries four E-boxes in the 
promoter (74) and 1 µg of the Renilla luciferase vector pRL-TK (Promega). After 24 h of 
incubation, cultures were split into aliquots and further incubated for 24 h with 200 nM 
4HT. Cells were lysed and the luciferase activity was measured in duplicate by a dual-
luciferase reporter gene assay system (Promega). Data were normalized against the 
Renilla luciferase activity. 
 
CML patient samples 
Bone marrow mononuclear cells from 66 CML patients (median age of 55 at the time of 
diagnosis) were studied. Patients were treated with imatinib and samples were taken up to 
36 months of treatment. The patients are from two hospitals: Hospital Universitario 
Marqués de Valdecilla (Santander, Spain) and Hospital Universitario Dr. Negrín (Las 
Palmas, Spain). The origin and characteristics of each patient included in our study are 
summarized in Supplementary Table S1. Patients were evaluated for hematological (HR), 
complete cytogenetic (CCR), major molecular (MMR) and complete molecular (CMR) 
responses and classified into optimal and suboptimal responses as described (75). 
Treatment failure was also recorded in nine patients. For our statistical analyses we have 
considered as non-responder those patients that did not achieve CCR at any time across 
the study. This study was approved by the ethics committees according to procedures 
approved by the two hospitals providing the samples. 
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Statistical analysis 
Groups were compared using the Mann-Whitney test.  Cumulative rates of different types of 
responses were estimated according to the Kaplan-Meier method and the significance in 
each group was tested by log rank test. MYC levels were dichotomized using their median 
value as cut-off. Patients with lack of response at the end the follow-up were considered 
as censored. Relationships between MYC and CCR and MMR were analyzed using the 
random-effects logistic regression model, where the probabilities of CCR or MMR were 
estimated as functions of MYC levels using the formula ( )
1
OR
OR
ep response
e
=
+
 (76). The 
efficacy of MYC expression to classify patients into responders and non-responders was 
studied by generating receiver operating characteristic (ROC) curves. MYC and BCR-ABL 
expression were compared by Sperman’s Rho and Pearson´s Correlation Coefficient. All 
p-values were calculated from two- side tests and values below 0.05 were considered 
significant.  
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Figure legends 
FIGURE 1. MYC induces aberrant DNA synthesis in the presence of imatinib in KmycB 
cells. A. Induction of MYC mRNA expression in KmycB cells in the presence of imatinib. 
Cells were treated with 0.5 μM imatinib and 75 μM ZnSO4 for 24, 48 or 72 h as indicated. 
MYC and histone H4 mRNA levels were determined by northern analysis. A picture of the 
filter after transfer showing the rRNAs stained with ethidium bromide is shown in each 
case to assess the loading and integrity of the RNAs. B. Induction of MYC expression in 
KmycB cells in the presence of imatinib. Cells were treated as in (A) for 48 or 72 h. 
Protein extracts were analyzed by immunoblotting with antibodies to MYC and α-tubulin 
as a loading control. C. Cell proliferation of KmycB cells treated with 0.5 μM imatinib and 
75 μM ZnSO4 as in A. D. DNA synthesis measured by thymidine (Thy) incorporation. 
Cells were treated for 72 h with imatinib and DNA synthesis was determined by 3H-
thymidine incorporation. Data are mean values from four experiments, and relative to the 
incorporation in untreated cells at each time point; bars indicate SEM. E. DNA synthesis 
measured by BrdU incorporation. KmycB cells were treated with 0.5 μM imatinib and 75 
μM ZnSO4 for 72 h. Data are mean values from four experiments. F. MYC induces an 
accumulation of cells with 4C DNA content in the presence of imatinib. KmycB cells were 
treated for 48 h with 0.5 μM imatinib and 75 μM ZnSO4 and the fraction of live cells in 
each cell cycle phase was determined by propidium iodide staining. The fraction of cells 
with 4C DNA content is indicated in each case. The data are mean values from five 
independent experiments. Bars indicate S.E.M. 
 
FIGURE 2. MYC induces aberrant DNA synthesis in the presence of imatinib in KMER4 
cells. A. Expression of MycER in KMER4 cells. Where indicated, cells were treated for 48 h 
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with 0.5 µM imatinib and 200 nM 4HT. The levels of the fusion protein MycER and the 
endogenous MYC were determined by immunoblot. Levels of α-tubulin were also 
determined to assess the protein loading. B. Activation of MYC in KMER4 cells. The 
activation of the MycER protein by 4HT was assayed by a luciferase assay using a 
promoter-luciferase construct containing four MYC-responsive elements (pGL2-M4-luc) 
upstream of the firefly luciferase gene. 24h after transfection, cells were treated with 200 nM 
4HT for an additional 24 h and the luciferase activity determined, normalized to the Renilla 
luciferase internal control. Data represent the mean of three independent experiments; bars 
indicate SEM. C. Cell proliferation assay of KMER4 cells treated with 0.5 μM imatinib and 
200 nM 4HT for 72 h. D. DNA synthesis measured by thymidine (Thy) incorporation. Cells 
were treated for 72 h with imatinib and DNA synthesis was determined by 3H-thymidine 
incorporation. Data are mean values from three experiments, and relative to the 
incorporation in untreated cells at each time point; bars indicate SEM. E. DNA synthesis 
measured by BrdU incorporation. KMER4 cells were treated with 0.5 μM imatinib and 200 
nM 4HT for 72 h. Data are mean values from three experiments. F. MYC induces an 
accumulation of cells with 4C DNA content in the presence of imatinib. KMER4 cells were 
treated for 48 h with 0.5 μM imatinib and 200 nM 4HT and the fraction of live cells in each 
cell cycle phase was determined by propidium iodide staining. The fraction of cells with 4C 
DNA content is indicated in each case. The data are mean values from three independent 
experiments. G. MYC induces DNA synthesis in 4C DNA cells treated with imatinib. Double 
labeling with BrdU and propidium iodide (PI) showing DNA synthesis in G2 cells.  KMER4 
cells were treated for 48 h with 0.5 µM imatinib and 200 nM 4HT (KMER4 cells). The 
percentage of cells with BrdU incorporated (above unlabelled controls) is indicated in each 
case. 
 
FIGURE 3. MYC does not increase imatinib-induced apoptosis and imatinib-mediated 
proliferation arrest is required for MYC-induced DNA synthesis. A. KmycB cells were treated 
with 0.5 µM imatinib and 75 µM ZnSO4 for 48 h and the fraction cells with sub-G1 DNA 
content was determined by PI staining and flow cytometry. The data are mean values from 
three independent experiments. Bars indicate SEM. B. The fraction of cells with cell surface 
annexin V binding was determined by flow cytometry with annexin V-FITC. The data are 
mean values from three independent experiments. Bars indicate SEM. C. Internucleosomal 
DNA fragmentation assay for KmycB cells treated with 0.5 µM imatinib (Imat.) and 75 µM 
ZnSO4 for 48 h as indicated. D. KmycBcl2 cells were treated for the 48 h with 0.5 µM 
imatinib and 70 µM ZnSO4 and analysed by immunoblot. Lysates of K562 and KLBcl2v 
were also included as negative and positive controls, respectively. E Immunoblot analysis 
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showing the expression of MYC and actin (as loading control) in KmycBcl2 cells treated with 
0.5 μM imatinib and 70 μM ZnSO4 as indicated. F. Cell proliferation curve showing the partial 
resistance to imatinib of KmycBcl2. The cells were treated with 70 μM ZnSO4 and 0.5 μM 
imatinib as indicated and counted up to 72 h. K562 and KLBcl2v were also included as 
controls. G. DNA synthesis measured by thymidine incorporation. Cells were treated for 72 h 
with imatinib and DNA synthesis was determined by 3H-thymidine incorporation. Data are 
mean ± SEM from three experiments, and relative to the thymidine incorporation in 
untreated cells at each time point. The data corresponding to KmycB are the same of Fig. 1, 
repeated here for better comparison. H. MYC induces an accumulation of cells with 4C DNA 
content in the presence of imatinib. KmycBcl2 cells were treated for 48 h with 0.5 μM 
imatinib and 75 μM ZnSO4 and the fraction of live cells in each cell cycle phase was 
determined by propidium iodide staining. The fraction of cells with 4C DNA content is 
indicated in each case. The data are mean values from three independent experiments 
 
FIGURE 4. MYC expression in CML patients. A. MYC mRNA expression between 
samples from CML patients at different stages of the disease. Each box refers to the 
range defined by the 25th and the 75th percentiles and the line indicates the median 
value. HC, healthy controls; DG, diagnosis; HR, hematological response within the first 3 
months of treatment; RE, response to imatinib (at least CCR); NR, no response to 
imatinib; BC, blastic crisis. n, number of RNA samples. ***, p <0.001. The mean of three 
replicates are plotted.  B.  MYC expression during CML evolution. The graphs show the 
expression of MYC and BCR-ABL during treatment of ten representative patients, 
including four that responded (R) and six patients that did not respond to imatinib (NR). 
These include two blast crisis (BC). Note that the scales are different. Patient’s 
identification appears in cursive. C. Upper panels: Immunoblots showing the MYC protein 
levels in lysates from bone marrow cells from CML patients at diagnosis (DG) and at CMR  
as indicated. Lower graph: quantification of the MYC protein signals with respect to ERK2 
or total proteins stained with Coomasie Blue (C.B.). The data are mean values and bars 
indicate S.E.M. 
 
FIGURE 5. MYC levels are higher in non-responder patients. A. Probability of response 
(CCR and MMR) after 18 months of treatment as function of MYC mRNA levels. Data are 
from 36 patients in CCR and 24 patients in MMR. Probabilities were estimated using 
random-effects logistic regression. B. Response to imatinib treatment according to MYC 
expression at diagnosis. The MYC levels were classified as “high” or “low” with respect to the 
median value at diagnosis, (0.153) and the MYC levels were plotted against the response to 
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imatinib during treatment (n = 28). C. MYC as a marker of the response to imatinib. ROC 
curves were plotted for MYC and BCR-ABL expression in patients at diagnosis and in 
responders (CCR, MMR or CMR) (right) or in patients that did not respond to treatment 
(left). The area under the MYC curve is indicated in each case. The star marks the MYC cut-
off value (0.058 with a sensitivity of 0.89 and specificity of 0.65).  
 
FIGURE 6. Lack of correlation between MYC and BCR-ABL expression in CML patients. 
Relationship between BCR-ABL and MYC levels in patients at diagnosis, in hematological 
response, non-responders, and in blastic crisis. The solid line indicates the linear prediction. 
Each point represents the mean of two or three mRNA determinations for each gene. 
Sperman’s Rho and Pearson´s Correlation Coefficient are indicated in each case.  
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Table 1: Clinicopathological characterístics of CML patients 
 
Gender 
 Female: 28 
 Male: 38 
 
Mean age at diagnosis 
 54 years (range 26-83) 
 
Bcr-Abl transcript 
 p210 b3a2: 50 
 p210 b2a2: 14 
 p210 b2a2 and p190: 2  
 
Stage at the end of the study 
 Chronic phase: 57 
 Accelerated phase: 0 
 Blast crisis: 9 
 
Response to treatment at the end of the study by cytological, cytogenetic and molecular 
status 
 Too early to evaluate response: 3 
 HR : 8 
 mCR : 7 
 CCR : 7 
 MMR: 24 
 CMR: 17 
 
Response to treatment at the end of the study (as ELN recommendations (75)) 
 Too early to evaluate response: 3 
Failure: 9   (8 HR, 1 mCR ) 
 Suboptimal response: 10 (6 mCR, 1 MCR, 1 CCR, 1 MMR, 1CMR) 
 Optimal response: 40 (6 CCR, 21 MMR, 13 CMR) 
 No data to evaluate response with these criteria: 4 (1 CCR, 2 MMR, 1CMR) 
 
Treatment   
Only imatinib: 31 
 IFN first line + imatinib: 22 
 HU/BU first line + imatinib: 13 
 
Abbreviations: HR haematological response, mCR minor cytogenetic response, CCR 
complete cytogenetic response, MMR major molecular response, CMR complete 
molecular response.  
 
  
 
A B
Figure 1.  Albajar et al
- +    +     +    - - - +    +    +     - Zn2+
24   24   48   72   24   48   72   24   48   72   72     h
- - - - +    +    +    +     +    +     - Imatinib
Myc endo.
Myc exog.
- - +       +       +       +       - 0.5 μM Imatinib
MYC
48                           72            h
- +        - +       - +       - 75 μM Zn2+
C
Histone H4
rRNAs
D
α-tubulin
K562
KmycB
40
60
80
100
nc
or
po
ra
tio
n 
(%
)
5
10
15
FE
- +    - - - +    +   - - 0.5 µM Imat.
- - +       - - - - +   + 2.5 µM Imat.
0
20T
hy
 in
- - - - +    - +    - + Zn2+
0
- +        - + Zn2+
- - +       + Imat.
10
15
20
C
 D
N
A 
co
nt
en
t  
(%
)
nc
or
po
ra
tio
n 
(%
)
50
100
0
5 
- +       - + Zn2+
C
el
ls
 w
ith
 4
- - +       + Imat.
B
rd
U
 in
0
- +       - + Zn2+
- - +       + Imat.
Figure 2.  Albajar et al
A B
- +         - +      - +     4HT
M ER
KMP                  KMER4
- - - - +     +    Imatinib
ct
iv
ity
 (%
)
2
3
m
l x
 1
05 10
15
C
MYC endo.
yc
α-tubulin
E
Lu
ci
fe
ra
se
 a
c
- +    4HT
0
1
- - +       +    Imat.
- +        - +    4HT
C
el
ls
/m
0
5
D
in
co
rp
or
at
io
n 
(%
)
15
30
45
40
60
80
100
hy
 in
co
rp
or
at
io
n 
(%
)
GF
- - +       +    Imat.
- +       - +    4HT
B
rd
U
 
00
20
- - +       +    Imat.
- +        - +    4HT
Th
Imatinib + 4HT
%
Imatinib
37.9%
U
 fl
uo
re
sc
en
ce
10
15
20
h 
4C
 D
N
A 
co
nt
en
t (
%
)
Propidium Iodide fluorescence
62.1
B
rd
- +       - + 4HT
- - +       + Imat.
0
5
C
el
ls
 w
ith
Figure 3.  Albajar et al
B
20
(%
)
A
Zn2+  - +     - +
Imat.  - - +     +
MW
C
+ + Imatinib
0
10
20
30
Su
b-
G
1 
ce
lls
 (%
)
0
10
+ + Imatinib
An
ne
xi
n 
V-
po
si
tiv
e 
ce
lls
 
- +      - +   Zn2+
- -         
- +     - +   Zn2+
- -          
D F
- - - - - +     - +   Zn2+
Bcl2
KLBcl2v K562 KmycBcl2
- +       - +     - - +      +   Imatinib K562 + Imat.
KLBcl2v
KLBcl2v + Imat.
K562
15
20
Actin
Actin
MYC
- - +     +  Imatinib
- +       - +   Zn2+
1             2             3  days  
  
KmycBcl2
KmycBcl2 + Zn2+
KmycBcl2 + Imat.
KmycBcl2 + Zn2++ Imat.
0
5
10
E
G H
10
15
20
A 
co
nt
en
t (
%
)
60
80
100
or
at
io
n 
(%
)
KmycB
KmycBcl2
or
at
io
n 
(%
)
or
at
io
n 
(%
)
- +        - + Zn2+
- - +       + Imatinib
0
5
C
el
ls
 w
ith
 4
C
 D
N
A
- +         - - +   + Imatinib
0
20
40
- - - +    - + Zn2+
Th
y 
in
co
rp
o
Th
y 
in
co
rp
o
Th
y 
in
co
rp
o
Figure 4. Albajar et al                                                
A
***
0.6
0.8
***
***
***
B
0.5 1.6 0.5 1.6
MYC BCR-ABL
HC      DG       HR     RE        NR      BC
n = 10 29 52 57 15 12
0.4
0.2
0.0
0.1
0.2
0.3
0.4
0 10 20 30 40
0.4
0.8
1.2
R         11A
0.1
0.2
0.3
0.4
0 10 20 30 40
0.4
0.8
1.2
R          12C
0.2
0.3
0.4
0.5
0.8
1.2
1.6
R         67G
0 1
0.2
0.3
0.8
1.2
1.6
R        89M
                                 
0
0.1
10 20 30 40
0.4
0
.
10 20 30 40
0.4
0
0.1
0.2
0.3
0.4
0.5
5 10 15 20
0
0.4
0.8
1.2
1.6
NR         31G
0
0.1
0.2
0.3
2 4 6 8 10
0.4
0.8
1.2
1.6
NR         64G 
M
YC
 e
xp
re
ss
io
n
B
C
R
-AB
L expressi
C 1    2    3   4    5   6   7    8    1    2    3    4  Patient 
DG                          CMR    
ERK2
MYC
0 4
0.5
0.6
0.7
0.6
0.8
NR         511B
1.5
2.0
6
8
58SNRBC
0.1
0.2
0.3
0 5 10 15 20 25
1
2
3
4
5NR         57P
ion
0.1
0.2
0.3
0.4
0.5
0 5 10 15
0.5
1.0
1.5
2.0
2.5
3.0
NR        43M
9   10  11  12 13  14  15   5   6    7 Patient 
ERK2
MYC
DG                       CMR
16 17 18 19 20 21 22 23 24 5 7 8 Patient
DG                              CMR
0.1
0.2
0.3
.
0 2 4 6 8
0.2
0.4BC
0.5
1.0
0 2 4 6 8
2
4
Months of treatment
                        
C.B.
MYC
si
on
1.8
R
el
at
iv
e 
ex
pr
es
s
0.0
0.6
1.2
DG CMR
Figure 5. Albajar et al                                                  
A
ul
ar
 r
es
po
ns
e 1.0
0.8
0.6
Low MYC
0.4
0.6
f r
es
po
ns
e CCR
MMR
p = 0.002
p = 0.003
B
Months of treatment
403020100
M
aj
or
 m
ol
ec
u
0.4
0.2
0.0
High MYC
0.0
0.2
Pr
ob
ab
ili
ty
 o
0.0 0.2 0.4 0.6 0.8 1.0
MYC expression
C
Diagnosis vs. Non-responders
Se
ns
iti
vi
ty
)
1
0.8
Diagnosis vs. Responders
10.80.60.40.20
MYC (0.44)
BCR-ABL
Tr
ue
 p
os
iti
ve
 r
at
e 
(S
0.6
0.4
0
0.2
10.80.60.40.20
MYC (0.85)
BCR-ABL
False positive rate (1-specificity)
Figure 6. Albajar et al
Diagnosis
2.5 n =  29
Hematologic  response
2.5 n =  43
2
0.0
0.5
1.0
1.5
2.0
0.2 0.4 0.6
R2 = 0.315
P =  0.002
B
C
R
-A
B
L
0.0
0.5
1.0
1.5
2.0
0.2 0.4
R = 0.000
P =  0.899
B
C
R
-A
B
L
Blastic crisis
n =  9
R2 = 0.060
P =  0.524
B
C
R
-A
B
L
1.0
1.5
2.0
2.5
3.0
B
C
R
-A
B
L
Non Responders
n =  13
R2 = 0.029
P =  0.578
1.0
1.5
2.0
2.5
3.0
0.2 0.4 0.6 0.8 1.0
MYC
0.0
0.5
0.2 0.4 0.6 0.8 1.0
0.0
0.5
MYC
